– USA, MA – Bone Biologics Corporation (Nasdaq: BBLG/BLGW), a developer of orthobiologic products for spine fusion markets, today announced the appointment of Rob Gagnon to its Board of Directors effective immediately, filling the seat left by Erick Lucera, who resigned effective today.
About Robert E. Gagnon
Rob Gagnon is CFO of Remix Therapeutics, a clinical-stage company focused on small molecule-mediated reprogramming of RNA processing to address hard-to-drug disease drivers.
Mr. Gagnon brings more than 20 years of financial and commercial experience leading global finance operations. He served as an Operating Partner at Gurnet Point Capital, a healthcare venture capital and private equity fund. He was CBO and CFO at Verastem Oncology. Before that, he was CFO at Harvard Bioscience, Inc. Mr. Gagnon served as EVP, CFO, and Treasurer at Clean Harbors, Inc. as well as CAO and Controller at Biogen Idec, Inc. Mr. Gagnon worked in a variety of senior positions at Deloitte & Touche, LLP, and PricewaterhouseCoopers, LLP.
He holds an MBA from the MIT Sloan School of Management and a BA in Accounting from Bentley College.
Mr. Gagnon currently serves on the Board of Directors at Verastem Oncology and Purple Biotech.
About Bone Biologics
Bone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking work with select strategic partners that build on the preclinical research of the Nell-1 protein. Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications.
For more information: https://www.bonebiologics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.